Navigation Links
Oxygen Biotherapeutics, Inc. Expands Board of Directors
Date:10/26/2009

DURHAM, N.C., Oct. 26 /PRNewswire-FirstCall/ -- Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBO) today announced the expansion of the company's board of directors with the addition of two new members. Appointed to the company's board were Rene A. Eckert and The Honorable William A. Chatfield. With their addition, the company board now has eight members.

Bill Chatfield most recently served as the Director of the U. S. Selective Service System from November of 2004 to May of this year, having been nominated by President George W. Bush and confirmed by the U.S. Senate. He was directly responsible to the President for the management of the Selective Service System. His background includes more than 30 years of experience working with the executive and legislative branches of the Federal government.

Rene Eckert was Chairman, CEO & Partner at Boehme Filatex Inc. of Reidsville, NC from 1981 to 2007. He started the specialty chemical company with two partners in 1981. They formed the company into a leading North American textile chemical corporation with subsidiaries in Canada and Mexico. In 2007 the corporation was sold to an international dyestuff company (Dystar).

"I'm very pleased that these two gentlemen have agreed to join our board," said Chris Stern, company chairman and CEO. "Rene Eckert has the business acumen and experience in product R & D, production scale up, and product manufacturing to help us bring Oxycyte(TM)-based products to the market. What Bill Chatfield brings to the table is the kind of Federal government experience and contacts, including the Department of Defense, that can be very helpful as we grow our Defense Medicine(TM) business plan. Our board and company will be stronger with their involvement."

About Oxygen Biotherapeutics, Inc.

Oxygen Biotherapeutics, Inc. is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and Defense Medicine(TM). The company has developed a perfluorocarbon (PFC) therapeutic oxygen carrier and liquid ventilation product (Oxycyte(TM)) and has out-licensed an implantable glucose sensor. These products are based upon core technologies that include biomedical applications for PFCs as well as medical and industrial applications for biosensors. Each of the product candidates is designed with advantages over currently marketed products in major markets including traumatic brain injury, sickle cell crisis, trauma, wound care, decompression sickness, acute respiratory distress syndrome, stroke, myocardial infarction, surgery, diabetes wounds and ulcers, and cosmetic applications which are being marketed under the Dermacyte name. More information is available at www.oxybiomed.com.

SOURCE Oxygen Biotherapeutics, Inc.


'/>"/>
SOURCE Oxygen Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. New Oxygen Biotherapeutics, Inc. Investor Presentation Available on Company Website
2. Oxygen Biotherapeutics, Inc. Seeks Shareholder Approval for Reverse Stock Split
3. Oxygen Biotherapeutics, Inc. to Present at Investment Conferences in New York and Zurich
4. Oxygen Biotherapeutics, Inc. Files 10-K for Fiscal Year Ended April 30, 2009
5. Oxygen Biotherapeutics, Inc. Announces Closing of Private Placement Financing Agreement
6. Brain Monitor Eliminates Need for Routine Oxygen With Propofol - Friedberg's Triad Unveiled
7. Oxygen Biotherapeutics, Inc. Signs Supply Agreement for Clinical-Grade Oxycyte for Clinical Trials and Future Needs
8. Oxygen Biotherapeutics, Inc. CEO Posts New Blog Entry
9. Webcast Alert: Oxygen Biotherapeutics, Inc. Investor Meeting in Zurich, Switzerland
10. Oxygen Biotherapeutics, Inc. Adds Oxycyte TBI Clinical Trial Sites in Israel
11. Oxygen Biotherapeutics, Inc. Expands Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... ... This CAST literature review and report looks at problems caused by the current ... in countries that are major global commodity exporters and importers, which show that asynchrony ... level presence (LLP) puts large volumes of trade worth billions of dollars at risk. ...
(Date:12/8/2016)... , Dec. 8, 2016 Soligenix, Inc. (OTCQB: ... focused on developing and commercializing products to treat rare ... today that it will be hosting an Investor Webcast ... on the origins of innate defense regulators (IDRs) as ... of oral mucositis and the recently announced and published ...
(Date:12/8/2016)... HOWELL, N.J. , Dec. 8, 2016 /PRNewswire/ ... aquatic augmentation remediation technologies and selected NewTechBio,s NT-MAX ... , a microbial based beneficial bacteria, in conjunction ... Inc., to correct deficiencies with National Pollutant Discharge ... basin 281-8H has experienced a steady history of ...
(Date:12/8/2016)... -- Partnering to fuel Philadelphia,s innovative ... Southeastern Pennsylvania (" Ben Franklin "); ... Blue Cross; and Safeguard Scientifics ("Safeguard") (NYSE: ... million funding initiative over a four year period to ... a burgeoning economic vitality in digital health, Ben ...
Breaking Biology Technology:
(Date:12/6/2016)... Biomet Holdings, Inc. (NYSE and SIX: ZBH) (the "Company") today ... principal amount of its 1.414% senior unsecured notes due 2022 ... notes due 2026. The closing of the ... the satisfaction of customary closing conditions.  The notes will pay ... The Company intends to use the net proceeds from the ...
(Date:12/2/2016)... , Dec. 1, 2016   SoftServe ... announced BioLock , an electrocardiogram (ECG) biosensor ... monitoring, a key IoT asset. The smart system ... a vehicle,s steering wheel and mobile devices to ... touch. As vehicle technology advances, so ...
(Date:11/29/2016)... Nearly one billion matches per second with DERMALOG,s ... ... DERMALOG is Germany's largest Multi-Biometric ... Management. (PRNewsFoto/DERMALOG Identification Systems) ... DERMALOG is Germany's largest Multi-Biometric supplier: The company's Fingerprint Identification System is ...
Breaking Biology News(10 mins):